Latest filings (excl ownership)
8-K
Results of Operations and Financial Condition
14 May 24
10-Q
2024 Q2
Quarterly report
14 May 24
S-8
Registration of securities for employees
5 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
7 Mar 24
10-Q
2024 Q1
Quarterly report
13 Feb 24
8-K
Results of Operations and Financial Condition
13 Feb 24
8-K
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
29 Jan 24
DEFA14A
Additional proxy soliciting materials
26 Jan 24
DEF 14A
Definitive proxy
26 Jan 24
8-K
Results of Operations and Financial Condition
12 Dec 23
10-K
2023 FY
Annual report
12 Dec 23
8-K
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
6 Nov 23
424B5
Prospectus supplement for primary offering
3 Nov 23
8-K
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
26 Oct 23
8-K
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress
23 Oct 23
EFFECT
Notice of effectiveness
11 Oct 23
CORRESP
Correspondence with SEC
6 Oct 23
CORRESP
Correspondence with SEC
6 Oct 23
S-3/A
Shelf registration (amended)
3 Oct 23
CORRESP
Correspondence with SEC
3 Oct 23
UPLOAD
Letter from SEC
26 Sep 23
S-3
Shelf registration
19 Sep 23
8-K
Updated Phase 1 results selected for a poster presentation at ESMO 2023
18 Sep 23
8-K
Amendments to Articles of Incorporation or Bylaws
15 Sep 23
8-K
ESSA Pharma Provides Corporate Update and Reports Financial Results for Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing
8 Aug 23
10-Q
2023 Q3
Quarterly report
8 Aug 23
8-K
ESSA Pharma Appoints Lauren Merendino to its Board of Directors
6 Jun 23
8-K
ESSA Pharma Provides Corporate Update and Reports Financial Results for Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing
9 May 23
10-Q
2023 Q2
Quarterly report
9 May 23
8-K
ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer
12 Apr 23
8-K
Submission of Matters to a Vote of Security Holders
10 Mar 23
8-K
Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study
7 Feb 23
10-Q
2022 Q1
Quarterly report
7 Feb 23
DEF 14A
Definitive proxy
24 Jan 23
8-K
ESSA Pharma Provides Corporate Update and Reports Financial Results for Clinical and Corporate Highlights for 2022 Fiscal Year
13 Dec 22
10-K
2022 FY
Annual report
13 Dec 22
8-K
ESSA Provides an Update on its Clinical Collaboration with Janssen
31 Oct 22
8-K
Regulation FD Disclosure
26 Oct 22
8-K
ESSA Pharma Appoints Philip Kantoff to its Board of Directors
13 Sep 22
10-Q
2022 Q3
Quarterly report
4 Aug 22
Latest ownership filings
4
Peter Virsik
6 May 24
4
Richard M Glickman
25 Apr 24
4
Peter Virsik
5 Apr 24
144
Notice of proposed sale of securities
5 Apr 24
4
SANFORD S ZWEIFACH
28 Mar 24
4
Marella Thorell
28 Mar 24
4
Gary Sollis
28 Mar 24
4
Scott Requadt
28 Mar 24
4
Lauren Merendino
28 Mar 24
4
John Alexander Martin
28 Mar 24
4
Philip W. Kantoff
28 Mar 24
4
Richard M Glickman
28 Mar 24
4
FRANKLIN M BERGER
28 Mar 24
4
David S. Wood
28 Mar 24
4
Peter Virsik
28 Mar 24
4
David Ross Parkinson
28 Mar 24
4
Alessandra Cesano
28 Mar 24
4
Peter Virsik
5 Mar 24
SC 13G/A
PFM Health Sciences, LP
14 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
BB BIOTECH AG
13 Feb 24
SC 13G
MORGAN STANLEY
8 Feb 24
4
Peter Virsik
7 Feb 24
4
Peter Virsik
6 Feb 24
SC 13G/A
Soleus Capital, LLC
23 Jan 24
4
Peter Virsik
17 Jan 24
144
Notice of proposed sale of securities
16 Jan 24
4
Scott Requadt
16 Jan 24
144
Notice of proposed sale of securities
12 Jan 24
4
Peter Virsik
8 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
4
David Ross Parkinson
18 Dec 23
4
David S. Wood
24 Nov 23
4
FRANKLIN M BERGER
22 Nov 23
4
FRANKLIN M BERGER
16 Nov 23
3
Lauren Merendino
6 Jun 23
SC 13G/A
BB BIOTECH AG
14 Feb 23
SC 13G/A
PFM Health Sciences, LP
14 Feb 23
SC 13G/A
Soleus Capital, LLC
14 Feb 23
SC 13G/A
Avidity Partners Management LP
14 Feb 23